CuraGen and TopoTarget Announce Initiation of NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer
14th Nov 2006, 18:19 GMT
CuraGen Corp and TopoTarget A/S announced the initiation of patient dosing in a Phase II clinical trial evaluating the antitumor activity of intravenous PXD101, a small molecule histone deacetylase inhibitor, for the treatment of ovarian cancer.
CuraGen and TopoTarget Announce Initiation of NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer related news:
- CuraGen and TopoTarget Announce Initiation of NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer — PR Newswire: All Releases
- CuraGen, TopoTarget initiate ovarian cancer trial — Pharmaceutical Business Review Latest News
- 1st Berlin Releases Research Update Following Callisto Pharmaceutical's Announcement of Initiation of Phase II Trial in Advanced Carcinoid Cancer Patients — Pharmaceuticals News from StratCenter.com
- First Berlin Releases Research Update Following Callisto Pharmaceutical's Announcement Of Initiation Of Phase II Trial In Advanced Carcinoid Cancer — Health News from Medical News Today
- New drug comb may lengthen ovarian cancer survival — Reuters: Health
- Systemic Treatment Before Surgery For Kidney Cancer Prolongs Patients' Survival — Health News from Medical News Today
- Scientists Design A PSA-activated Protoxin That Kills Prostate Cancer: Phase I Clinical Trial Is Under Way — Health News from Medical News Today
- A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens — British Journal of Cancer AOP
- Babies still an option for those with ovarian cancer? — Blogging Baby
- Isis Pharma's shares soar on cholesterol-drug Phase II data — MarketWatch.com - Top Stories – Sponsored by: CyberTrader
Latest news from Obstetrics/ Gynecology News from StratCenter.com:
- Acusphere Reports Q3 2006 Financial Results and Accomplishments
- Twin Cities Takes Action to Save Babies
- Substantial Regression of Atherosclerosis May Help Improve Diseased Arteries
- EDAP TMS SA to Participate in Int'l Urology Conferences
- Misonix Showcases SonicOne Ultrasonic Wound Debrider with Medline at MEDICA 2006 in Germany
- 8 Studies Evaluating Cytyc's Novasure System Presented at AAGL Meeting